

## REMARKS

Applicants submit these remarks in response to the Office Action dated April 20, 2004. Claims 1-9 and 17-25, previously withdrawn, have been cancelled. Claim 10 was previously cancelled, and previously pending claims 11 and 13-16 are cancelled herein. Claim 12 is amended to correct a typographical error and no new matter is added.


Claim 12 is objected to in view of the missing words. This typographical error is corrected by amendment herein.

Claims 11 and 13-16 are rejected under 35 U.S.C. § 101 and 112, first paragraph. Claims 11 and 13-16 are also rejected under 35 U.S.C. § 112, first paragraph (written description). The Examiner agrees that the polypeptide of SEQ ID NO:2 is a plasmolipin, but has maintained the rejection to the extent that the claims cover variants of this sequence. Without acquiescing to the ground of rejection, and in order to advance the prosecution of allowable subject matter, applicants have cancelled claims 11 and 13-16.

All of the claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.

If questions remain regarding this application, the Examiner is invited to contact the undersigned at (206) 628-7650.

Respectfully submitted,  
David Duhl et al.  
DAVIS WRIGHT TREMAINE LLP

By   
Jane E. R. Potter  
Registration No. 33,332

2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Phone: (206) 628-7650  
Facsimile: (206) 628-7699